Literature DB >> 19411848

Conserved ATRMec1 phosphorylation-independent activation of Chk1 by single amino acid substitution in the GD domain.

Elizabeth Pereira1, Yinhuai Chen, Yolanda Sanchez.   

Abstract

Chk1 is a conserved kinase that comprises the first line of defense against DNA damage and replication blocks. Chk1 consists of two primary domains, the well conserved N-terminal kinase domain and the non-catalytic C-terminal domain that contains the two highly conserved TRF and GD sub-domains. Several studies suggested that the C-terminus of Chk1 acts as an inhibitory domain and that phosphorylation of the C-terminus by ATR serves to activate Chk1 by relieving the inhibitory effect of the C-terminus on the N-terminal catalytic domain. However, work carried out in many systems showed that phosphorylation on ATR sites was necessary but not sufficient to increase Chk1 kinase activity. In a recent manuscript we described a single amino acid substitution at an invariant Leucine in the conserved GD domain of the yeast Chk1 C-terminus (L506R) that led to a Chk1 protein that no longer required ATR(Mec1) phosphorylation at conserved sites for its function, and relieved the requirement of an upstream mediator, Rad9 (53BP1 homolog), for Chk1 activation. Here we show that this single amino acid substitution in the GD domain also led to constitutive phosphorylation of yeast and human Chk1 on ATR(Mec1) sites, suggesting that the protein was in a conformation in which it could be readily phosphorylated by ATR(Mec1). Unlike the phospho-mimetic mutants in earlier studies, the L505R and L449R modifications led to increased Chk1 activity both in vitro and in vivo. Therefore, we have uncovered a conserved mechanism for Chk1 regulation separate from the role of known ATR phosphorylation sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411848      PMCID: PMC4045630          DOI: 10.4161/cc.8.11.8737

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

1.  The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation.

Authors:  P Chen; C Luo; Y Deng; K Ryan; J Register; S Margosiak; A Tempczyk-Russell; B Nguyen; P Myers; K Lundgren; C C Kan; P M O'Connor
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

2.  Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345.

Authors:  Kecheng Jiang; Elizabeth Pereira; Melissa Maxfield; Beatriz Russell; Dawn Marie Goudelock; Yolanda Sanchez
Journal:  J Biol Chem       Date:  2003-04-03       Impact factor: 5.157

3.  Activation of Xenopus Chk1 by mutagenesis of threonine-377.

Authors:  S X Wang; W G Dunphy
Journal:  FEBS Lett       Date:  2000-12-29       Impact factor: 4.124

4.  Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest.

Authors:  Holly Capasso; Carmela Palermo; Shanhong Wan; Hui Rao; Ulrik P John; Matthew J O'Connell; Nancy C Walworth
Journal:  J Cell Sci       Date:  2002-12-01       Impact factor: 5.285

5.  Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast.

Authors:  A Lopez-Girona; K Tanaka; X B Chen; B A Baber; C H McGowan; P Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.

Authors:  H Zhao; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

8.  Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation.

Authors:  Magtouf Gatei; Katie Sloper; Claus Sorensen; Randi Syljuäsen; Jacob Falck; Karen Hobson; Kienan Savage; Jiri Lukas; Bin-Bing Zhou; Jiri Bartek; Kum Kum Khanna
Journal:  J Biol Chem       Date:  2003-02-14       Impact factor: 5.157

9.  ATRMec1 phosphorylation-independent activation of Chk1 in vivo.

Authors:  Yinhuai Chen; Julie M Caldwell; Elizabeth Pereira; Robert W Baker; Yolanda Sanchez
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

10.  Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.

Authors:  Deborah Wilsker; Eva Petermann; Thomas Helleday; Fred Bunz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-17       Impact factor: 11.205

View more
  5 in total

1.  Transformation/transcription domain-associated protein (TRRAP)-mediated regulation of Wee1.

Authors:  Teresa M Calonge; Majid Eshaghi; Jianhua Liu; Ze'ev Ronai; Matthew J O'Connell
Journal:  Genetics       Date:  2010-03-01       Impact factor: 4.562

2.  Regulatory motifs in Chk1.

Authors:  Michael L Caparelli; Matthew J O'Connell
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

3.  Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage.

Authors:  Xiangzi Han; Jinshan Tang; Jingna Wang; Feng Ren; Jinhua Zheng; Megan Gragg; Philip Kiser; Paul S H Park; Krzysztof Palczewski; Xinsheng Yao; Youwei Zhang
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

4.  Autoregulatory mechanisms of phosphorylation of checkpoint kinase 1.

Authors:  Jingna Wang; Xiangzi Han; Youwei Zhang
Journal:  Cancer Res       Date:  2012-08-01       Impact factor: 12.701

5.  An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.

Authors:  Tatiana N Moiseeva; Yandong Yin; Michael J Calderon; Chenao Qian; Sandra Schamus-Haynes; Norie Sugitani; Hatice U Osmanbeyoglu; Eli Rothenberg; Simon C Watkins; Christopher J Bakkenist
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-17       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.